Clinical Trial Detail

NCT ID NCT02541604
Title A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

Atezolizumab

Age Groups: child adult

No variant requirements are available.